MCID: LYM027
MIFTS: 57

Lymphopenia

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 29 54 6 43 15 71
Lymphocytopenia 12 62

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD9CM 34 288.51
MeSH 43 D008231
SNOMED-CT 67 48813009
ICD10 32 D72.810
UMLS 71 C0024312

Summaries for Lymphopenia

PubMed Health : 62 About lymphocytopenia: Lymphocytopenia (LIM-fo-si-to-PE-ne-ah) is a disorder in which your blood doesn’t have enough white blood cells called lymphocytes (LIM-fo-sites). These cells are made in the bone marrow along with other kinds of blood cells. Lymphocytes help protect your body from infection. Low numbers of lymphocytes can raise your risk of infection. Lymphocytopenia also is called lymphopenia.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and adenosine deaminase deficiency. An important gene associated with Lymphopenia is RAC2 (Rac Family Small GTPase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Interleukin-2 have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

Wikipedia : 74 Lymphocytopenia is the condition of having an abnormally low level of lymphocytes in the blood.... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 660)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 34.5 RAG1 PTPN22 IL10 IFNG FOXP3 CTLA4
2 adenosine deaminase deficiency 33.1 RAG1 JAK3 IL2RG
3 reticular dysgenesis 32.6 RAG1 JAK3 IL2RG
4 lupus erythematosus 31.0 PTPN22 IL10 IFNG FASLG CTLA4
5 cryptococcosis 30.7 SELL IL10 IFNG
6 t-cell leukemia 30.7 LCK JAK3 IL2RG IL2RA IL2
7 thymoma 30.7 PTPN22 LCK IL2 FOXP3 CTLA4
8 combined immunodeficiency, x-linked 30.6 RAC2 MYH7 IL7 IL2RG
9 combined t cell and b cell immunodeficiency 30.6 RAG1 JAK3 IL7R IL7 IL2RG IL2
10 t-cell adult acute lymphocytic leukemia 30.6 JAK3 IL2RA IL2 FOXP3
11 severe acute respiratory syndrome 30.6 IL2 IL10 IFNG
12 pancytopenia 30.6 IL2RA IFNG G6PC3 FOXP3 CD55
13 anemia, autoimmune hemolytic 30.5 IL2 FOXP3 CTLA4 CD55
14 exanthem 30.5 IL2 IL10 CTLA4
15 pulmonary sarcoidosis 30.5 IL2RA IL2 IFNG
16 graft-versus-host disease 30.5 IL2 IL10 IFNG FASLG FAS
17 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 PTPN22 IL2 CTLA4
18 hypereosinophilic syndrome 30.5 IL2RA IL2 IL10 IFNG
19 human immunodeficiency virus type 1 30.5 LCK IL7 IL2 IL10 IFNG
20 mycosis fungoides 30.5 IL7 IL2RA IL2 IFNG FOXP3 CTLA4
21 chickenpox 30.4 IL2 IL10 IFNG
22 autoimmune enteropathy 30.4 IL2RA FOXP3
23 crohn's disease 30.4 PTPN22 IL2 IL10 IFNG
24 leptospirosis 30.4 IL2 IL10 IFNG
25 erythema multiforme 30.4 IL2 IFNG FASLG FAS
26 idiopathic neutropenia 30.4 IL2RA IL10 FASLG
27 acute graft versus host disease 30.4 IL2RA IL2 IL10 IFNG FASLG
28 appendicitis 30.4 IL2 IL10 IFNG
29 adult t-cell leukemia 30.3 JAK3 IL2RA IL2 FOXP3 FAS CTLA4
30 t cell deficiency 30.3 SELL RAG1 IL7R IL7 IL2RG IL2
31 digeorge syndrome 30.3 RAG1 IL7 IL2RG FAS
32 acquired immunodeficiency syndrome 30.3 IL2RA IL2 IL10 IFNG
33 silicosis 30.3 IL10 FASLG FAS
34 meningitis 30.3 IL2 IL10 IFNG CD55
35 relapsing-remitting multiple sclerosis 30.3 IL7R IL2 IL10 IFNG FOXP3 FAS
36 severe combined immunodeficiency, x-linked 30.3 JAK3 IL7R IL7 IL2RG IL2RA IL2
37 sjogren syndrome 30.3 IL2RA IL10 FASLG FAS
38 psoriasis 30.3 PTPN22 IL7 IL2RA IL2 IL10 IFNG
39 colitis 30.3 IL2 IL10 IFNG FOXP3 CTLA4
40 thyroiditis 30.3 PTPN22 IL2 IL10 FOXP3 FASLG CTLA4
41 autoimmune hepatitis 30.3 IL10 FOXP3 FAS CTLA4
42 stevens-johnson syndrome/toxic epidermal necrolysis 30.3 IL2 IFNG FAS
43 severe combined immunodeficiency 30.3 RAG1 RAC2 MYH7 LCK JAK3 IL7R
44 systemic lupus erythematosus 30.3 PTPN22 LCK IL2RA IL2 IL10 IFNG
45 chronic graft versus host disease 30.3 IL2RA IL10 IFNG
46 stomatitis 30.2 IL2 IL10 IFNG
47 spotted fever 30.2 IL10 IFNG CTLA4
48 herpes zoster 30.2 IL2 IL10 IFNG
49 thrombocytopenia 30.2 SELL IL7 IL2 IL10 IFNG FOXP3
50 lymphoproliferative syndrome 30.2 IL2RA IL2 IL10 FASLG FAS CTLA4

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

MGI Mouse Phenotypes related to Lymphopenia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.45 CD55 CTLA4 FAS FASLG FOXP3 G6PC3
2 endocrine/exocrine gland MP:0005379 10.42 CTLA4 FAS FASLG FOXP3 G6PC3 IFNG
3 immune system MP:0005387 10.39 CTLA4 FAS FASLG FOXP3 G6PC3 IFNG
4 cardiovascular system MP:0005385 10.38 CTLA4 FAS FASLG FOXP3 IFNG IL10
5 cellular MP:0005384 10.34 FAS FASLG FOXP3 IFNG IL10 IL2
6 homeostasis/metabolism MP:0005376 10.33 CTLA4 FAS FASLG FOXP3 G6PC3 IFNG
7 digestive/alimentary MP:0005381 10.29 CTLA4 FAS FASLG FOXP3 IFNG IL10
8 mortality/aging MP:0010768 10.24 CTLA4 FAS FASLG FOXP3 G6PC3 IFNG
9 liver/biliary system MP:0005370 10.1 CTLA4 FAS FASLG FOXP3 IFNG IL10
10 neoplasm MP:0002006 9.97 FAS FASLG IFNG IL10 IL2 IL2RG
11 normal MP:0002873 9.85 CTLA4 FAS FASLG FOXP3 IFNG IL10
12 no phenotypic analysis MP:0003012 9.8 FOXP3 IFNG IL10 IL2 IL2RG IL7
13 respiratory system MP:0005388 9.73 CTLA4 FAS FASLG FOXP3 IFNG IL10
14 vision/eye MP:0005391 9.28 FAS FASLG FOXP3 IFNG IL10 IL2

Drugs & Therapeutics for Lymphopenia

PubMed Health treatment related to Lymphopenia: 62

If you have mild lymphocytopenia with no underlying cause, you may not need treatment . The disorder may improve on its own. If you have unusual infections, repeat infections, and/or infections that won't go away due to lymphocytopenia , you'll need treatment for the infections. If you have a disease or condition that's causing lymphocytopenia , your doctor will prescribe treatment for that illness. Treating the underlying problem will help treat the lymphocytopenia.

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2 Interleukin-2 Phase 4
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Etoposide Approved Phase 3 33419-42-0 36462
7
leucovorin Approved Phase 3 58-05-9 6006 143
8
Durvalumab Approved, Investigational Phase 3 1428935-60-7
9
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
10
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
11
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
12
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
13
Zinc Approved, Investigational Phase 3 7440-66-6 32051
14
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
15
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
16
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
19 Immunoglobulin G Phase 3
20 Topoisomerase Inhibitors Phase 3
21 Albumin-Bound Paclitaxel Phase 3
22 Antimitotic Agents Phase 3
23 Etoposide phosphate Phase 3
24 Podophyllotoxin Phase 3 518-28-5
25 Vitamin B Complex Phase 3
26 Folic Acid Antagonists Phase 3
27 Vitamin B9 Phase 3
28 Folate Phase 3
29 Antibiotics, Antitubercular Phase 3
30 Anti-Bacterial Agents Phase 3
31 Antifungal Agents Phase 3
32 Neurotransmitter Agents Phase 3
33 Antiemetics Phase 3
34 Gastrointestinal Agents Phase 3
35 Autonomic Agents Phase 3
36 Nutrients Phase 3
37 Trace Elements Phase 3
38 Micronutrients Phase 3
39 Whey Protein Phase 3
40 Dopamine Agents Phase 3
41 Dopamine D2 Receptor Antagonists Phase 3
42 Antioxidants Phase 3
43 Dopamine Antagonists Phase 3
44 Protective Agents Phase 3
45 glutamine Phase 3
46
Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
47
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
48
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Comparison of Campath−Tacrolimus vs IL2R MoAb−Tacrolimus/MMMF in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
2 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
3 Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study Unknown status NCT02976688 Phase 2, Phase 3
4 Fumaric Acid Esters Versus Fumaric Acid Esters Plus Narrow Band Type B Ultraviolet (UVB) in Patients With Severe Plaque Psoriasis Completed NCT01321164 Phase 3 Fumaric acid esters
5 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel
6 Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC Recruiting NCT01993810 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed Disodium
7 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Active, not recruiting NCT01120249 Phase 3 everolimus
8 Nutritional Supplementation for Esophageal Cancer Patients Undergoing Trimodality Therapy Not yet recruiting NCT04029857 Phase 3
9 The Critical Illness Stress-induced Immune Suppression Prevention Trial Terminated NCT00395161 Phase 3 Metoclopramide;Zinc;Selenium
10 A Randomised, Multicentric, Phase 2a Study Evaluating the Impact of an Immunotherapy by IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
11 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
12 A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients. Completed NCT02640807 Phase 2 Interleukin-7;Placebo
13 An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation Completed NCT00435084 Phase 1, Phase 2 APO866
14 A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma. Completed NCT00432107 Phase 2 APO866
15 A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma Completed NCT00431912 Phase 2 APO866
16 A Safety and Dose-escalation Study of Zinc Supplementation in Pediatric Critical Illness Completed NCT01062009 Phase 1, Phase 2 Zinc sulfate
17 Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma Completed NCT00613093 Phase 2 Temodar and O6-Benzylguanine (BG)
18 Ph IIb Study Evaluating the Safety & Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed NCT00771810 Phase 2 TXA127;TXA127;Placebo
19 Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Chronic Myeloid Leukemia on Standard Drug Therapy Completed NCT00815321 Phase 2
20 Pilot Study in AIDS-Related Lymphomas Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
21 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
22 A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
23 A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies Completed NCT00460694 Phase 1, Phase 2
24 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer Completed NCT00942578 Phase 2 Bevacizumab;Lenalidomide;Docetaxel;Prednisone
25 A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia Recruiting NCT03519464 Phase 2
26 International, Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts (ALC) in Patients With Sepsis Recruiting NCT03821038 Phase 2 Placebos
27 A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH) Recruiting NCT03338998 Phase 2 BAF312;Placebo
28 Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome Recruiting NCT03383380 Phase 1, Phase 2 Rapamycin
29 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
30 Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
31 Single Arm, Multicentre Study of Carfilzomib in Combination With Thalidomide and Dexamethasone (CaTD) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) Recruiting NCT03140943 Phase 2 Carfilzomib, Thalidomide and Dexamethasone
32 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
33 A Phase I/II Study of the Addition of Ixazomib to ONC201 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Recruiting NCT03492138 Phase 1, Phase 2 ONC201;Ixazomib;Dexamethasone
34 A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT03519997 Phase 2 Pembrolizumab;Bavituximab
35 CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Active, not recruiting NCT03139851 Phase 2 Cyclophosphamide 50mg;Pembrolizumab 100 MG in 4 ML Injection
36 EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Active, not recruiting NCT02001272 Phase 2 Paclitaxel + Carboplatin every 3 weeks;Carboplatin monotherapy every 3 weeks;Weekly Paclitaxel and Carboplatin
37 A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia Active, not recruiting NCT00195624 Phase 2 Cyclosporine
38 Study of the Role of Peripheral Acetylcholinesterase Inhibitor Pyridostigmine as Immunomodulators in a Population of Patients Living With Human Immunodeficiency Virus Infection. Enrolling by invitation NCT03312244 Phase 2 Pyridostigmine Bromide;Placebo
39 Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma: Comparison of Two Established Schedules Not yet recruiting NCT04019262 Phase 1, Phase 2 Temozolomide Oral Product
40 A Double-blind, Placebo-controlled, Crossover Study of Magnesium Supplementation in Patients With XMEN Syndrome Suspended NCT02496676 Phase 1, Phase 2
41 Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) Terminated NCT00839436 Phase 1, Phase 2 CYT107
42 Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC Terminated NCT00961376 Phase 2
43 Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial Terminated NCT00282438 Phase 1, Phase 2
44 A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects Completed NCT02211469 Phase 1 BMS-986104;Placebo
45 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers Completed NCT02860715 Phase 1 GX-I7;Placebo
46 A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers Completed NCT03144934 Phase 1 GX-I7;Placebo
47 A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma Completed NCT00091143 Phase 1 fludarabine phosphate
48 An Open Label Phase I Dose Escalation Study Of E7080 Completed NCT00121719 Phase 1 Lenvatinib
49 REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme Completed NCT00626483 Phase 1 basiliximab
50 Zenapax®-Activated Peptide ImmunoTherapy [ZAP IT] Completed NCT00626015 Phase 1 temozolomide

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

# Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

40
T Cells, B Cells, Bone, Lung, Bone Marrow, Kidney, Breast

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 7614)
# Title Authors PMID Year
1
Measles virus-induced immunosuppression in SLAM knock-in mice. 54 61
20200244 2010
2
Irradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia. 54 61
20075162 2010
3
Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. 54 61
19690616 2009
4
False negative results of QuantiFERON TB-2G test in patients with active tuberculosis. 54 61
19628910 2009
5
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. 54 61
19483649 2009
6
Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. 54 61
19351957 2009
7
Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare. 54 61
19438596 2009
8
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. 54 61
18971421 2009
9
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. 54 61
19136960 2009
10
Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. 54 61
18728247 2008
11
Priming of T cells to Fas-mediated proliferative signals by interleukin-7. 54 61
18441236 2008
12
IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. 54 61
18375155 2008
13
Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients. 54 61
18589120 2008
14
A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. 54 61
18610754 2008
15
Immunosuppression in islet transplantation. 54 61
18431511 2008
16
Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. 54 61
18205031 2008
17
Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. 54 61
18630487 2008
18
Immune defects in breast cancer patients after radiotherapy. 54 61
19087768 2008
19
Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. 54 61
18086347 2007
20
[Immunotherapy in radical surgery of colorectal carcinoma]. 54 61
18019635 2007
21
An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. 54 61
17664294 2007
22
Apoptosis does not contribute to the blood lymphocytopenia observed after intensive and downhill treadmill running in humans. 54 61
17987505 2007
23
Perspectives on interleukin-7 therapy in HIV infection. 54 61
19372891 2007
24
Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. 54 61
17457102 2007
25
Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. 54 61
17484867 2007
26
A three-base-deletion polymorphism in the upstream non-coding region of human interleukin 7 (IL-7) gene could enhance levels of IL-7 expression. 54 61
17373935 2007
27
Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. 54 61
17053062 2007
28
The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. 54 61
17198533 2007
29
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. 54 61
17289551 2007
30
Interleukin 7 receptor alpha-chain-mutation severe combined immunodeficiency without lymphopenia: correction with haploidentical T-cell-depleted bone marrow transplantation. 54 61
17201233 2006
31
Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. 54 61
17142786 2006
32
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. 54 61
16778146 2006
33
Follow up study on the immune response to low frequency electromagnetic fields in men and women working in a museum. 54 61
17291405 2006
34
Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. 54 61
16844418 2006
35
ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. 54 61
16799570 2006
36
Interleukin-7 partially rescues B-lymphopoiesis in osteopetrotic oc/oc mice through the engagement of B220+ CD11b+ progenitors. 54 61
16797412 2006
37
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. 54 61
16699374 2006
38
Severe combined immune deficiency in an adenosine deaminase-deficient patient. 54 61
16724639 2006
39
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. 54 61
16461915 2006
40
Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. 54 61
17080916 2006
41
Role of interleukin-7 in bone and T-cell homeostasis. 54 61
16313348 2005
42
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). 54 61
16131572 2005
43
Two-tiered universal newborn screening strategy for severe combined immunodeficiency. 54 61
16260163 2005
44
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. 54 61
16020503 2005
45
Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. 54 61
16277025 2005
46
Apoptotic markers on lymphocytes and monocytes are unchanged during single hemodialysis sessions using either regenerated cellulose or polysulfone membranes. 54 61
16175944 2005
47
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. 54 61
15905493 2005
48
Idiopathic CD4+ lymphocytopenia may be due to decreased bone marrow clonogenic capability. 54 61
15746558 2005
49
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. 54 61
15800326 2005
50
Abnormal interleukin-7 function in common variable immunodeficiency. 54 61
15598813 2005

Variations for Lymphopenia

ClinVar genetic disease variations for Lymphopenia:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYH7 NM_000257.4(MYH7):c.2389G>A (p.Ala797Thr)SNV Pathogenic/Likely pathogenic 42901 rs3218716 14:23894525-23894525 14:23425316-23425316
2 RAC2 NM_002872.5(RAC2):c.184G>A (p.Glu62Lys)SNV Pathogenic/Likely pathogenic 464885 rs1555908409 22:37628882-37628882 22:37232842-37232842
3 MYOC NM_000261.2(MYOC):c.1102C>T (p.Gln368Ter)SNV Likely pathogenic 7949 rs74315329 1:171605478-171605478 1:171636338-171636338
4 NEK1 NM_012224.3(NEK1):c.1021G>A (p.Ala341Thr)SNV Conflicting interpretations of pathogenicity 266046 rs189186475 4:170483347-170483347 4:169562196-169562196
5 JAK3 NM_000215.3(JAK3):c.2452G>A (p.Glu818Lys)SNV Uncertain significance 464099 rs374191135 19:17943637-17943637 19:17832828-17832828
6 NEK1 NM_001199397.2(NEK1):c.859C>G (p.Pro287Ala)SNV Uncertain significance 598999 rs35222922 4:170502002-170502002 4:169580851-169580851

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 SELL RAG1 PTPN22 LCK JAK3 IL7R
2
Show member pathways
13.88 RAC2 MYH7 JAK3 IL7R IL7 IL2RG
3
Show member pathways
13.73 JAK3 IL7R IL7 IL2RG IL2RA IL2
4
Show member pathways
13.59 RAC2 JAK3 IL7R IL7 IL2RG IL2RA
5
Show member pathways
13.49 RAC2 LCK JAK3 IL7R IL7 IL2RG
6
Show member pathways
13.43 RAG1 LCK JAK3 IL7R IL7 IL2RG
7
Show member pathways
13.35 RAC2 PTPN22 MYH7 IL7R IL7 IL2RG
8
Show member pathways
13.33 SELL RAC2 LCK JAK3 IL2RG IL2RA
9
Show member pathways
13.13 JAK3 IL2 IL10 IFNG FASLG FAS
10
Show member pathways
13.08 JAK3 IL7R IL7 IL2RG IL2RA IL2
11
Show member pathways
12.91 JAK3 IL2RG IL2RA IL2 IFNG FASLG
12
Show member pathways
12.84 JAK3 IL7R IL7 IL2RG IL2RA IL2
13 12.79 RAC2 JAK3 IL7R IL7 IL2RG IL2RA
14
Show member pathways
12.7 LCK JAK3 IFNG FASLG FAS
15
Show member pathways
12.68 LCK IL2 IL10 IFNG FAS CTLA4
16
Show member pathways
12.68 LCK JAK3 IL2RG IL2RA IL2 IL10
17
Show member pathways
12.66 LCK IL2RA IL2 IL10 IFNG
18
Show member pathways
12.64 RAC2 MYH7 IL2RA IL2 IL10 IFNG
19
Show member pathways
12.62 RAC2 LCK IL2 IFNG FASLG FAS
20
Show member pathways
12.5 RAC2 LCK IL2RG IL2RA IL2 CTLA4
21 12.41 LCK JAK3 IL2RG IL2RA IL2
22
Show member pathways
12.35 IL2RG IL2RA IL2 IL10
23
Show member pathways
12.29 JAK3 IL7R IL7 IL2RG IL2RA IL2
24
Show member pathways
12.27 RAC2 LCK JAK3 IL2RG IL2RA IL2
25
Show member pathways
12.24 JAK3 IFNG FASLG FAS
26
Show member pathways
12.19 RAG1 IL7R IL10 G6PC3 FASLG
27
Show member pathways
12.19 LCK JAK3 IL2RG IL2RA IL2 IFNG
28
Show member pathways
12.16 JAK3 IL2RG IL2 IL10 IFNG
29
Show member pathways
12.09 LCK IL2RG IL2RA IL2 IFNG FASLG
30 12.08 RAC2 LCK IL2 IL10
31 12.05 JAK3 IL2RG IL10 FASLG
32 12.01 SELL IL7R IL7 IL2RA IL2 IL10
33 11.97 IL7R IL7 IL2RA CD55
34 11.92 LCK JAK3 IL7R IL2RA IL2 IL10
35 11.92 RAG1 PTPN22 LCK JAK3 IL2RA IL2
36 11.88 SELL IL7R IL2 IL10 IFNG
37
Show member pathways
11.87 JAK3 IL2RG FOXP3
38 11.87 IL7R IL7 IL2RA IL2 IL10 IFNG
39
Show member pathways
11.84 IL2RA IL2 IFNG FOXP3 FASLG CTLA4
40
Show member pathways
11.78 IL2RG IL2RA IL2 IFNG FASLG
41 11.75 IL2 IL10 IFNG
42 11.74 PTPN22 LCK CTLA4
43 11.68 JAK3 IL2RG IL10
44 11.66 IL2 IFNG FASLG FAS
45
Show member pathways
11.63 JAK3 IL7R IL7 IL2RG IL2RA
46
Show member pathways
11.63 LCK JAK3 IL2RG IL2RA IL2 FOXP3
47 11.55 LCK IL7R IL2RA
48 11.51 IL10 IFNG FASLG FAS
49 11.5 RAG1 LCK JAK3 IL7R IL2RG
50 11.43 LCK IL2RG IL2RA IL2 IFNG

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.26 LCK FASLG FAS CD55
2 external side of plasma membrane GO:0009897 9.1 SELL IL7R IL2RG IL2RA FASLG CTLA4

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.05 PTPN22 JAK3 IL2RA IL2 CTLA4 CD55
2 positive regulation of gene expression GO:0010628 10.03 PTPN22 IL7R IL7 IFNG FOXP3
3 positive regulation of cell proliferation GO:0008284 10 RAC2 IL7R IL7 IL2 IFNG FASLG
4 MAPK cascade GO:0000165 9.96 JAK3 IL2RG IL2RA IL2
5 adaptive immune response GO:0002250 9.96 RAG1 JAK3 IL2 IFNG CTLA4
6 T cell receptor signaling pathway GO:0050852 9.88 PTPN22 LCK FOXP3 CTLA4
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.84 LCK FASLG FAS
8 negative regulation of inflammatory response GO:0050728 9.84 IL2RA IL2 IL10 FOXP3
9 B cell differentiation GO:0030183 9.83 RAG1 JAK3 IL10
10 positive regulation of T cell proliferation GO:0042102 9.79 JAK3 IL2RA IL2
11 negative regulation of T cell proliferation GO:0042130 9.78 IL2RA IL10 FOXP3 CTLA4
12 negative regulation of tumor necrosis factor production GO:0032720 9.77 PTPN22 IL10 FOXP3
13 T cell differentiation GO:0030217 9.76 PTPN22 LCK IL7R IL2
14 cytokine-mediated signaling pathway GO:0019221 9.76 JAK3 IL7R IL7 IL2RG IL2RA IL2
15 extrinsic apoptotic signaling pathway GO:0097191 9.74 IFNG FASLG FAS
16 T cell homeostasis GO:0043029 9.71 RAG1 JAK3 IL2RA FOXP3
17 negative regulation of interleukin-17 production GO:0032700 9.68 IFNG FOXP3
18 negative regulation of interleukin-10 production GO:0032693 9.68 JAK3 FOXP3
19 regulation of T cell proliferation GO:0042129 9.67 RAC2 CTLA4
20 interleukin-15-mediated signaling pathway GO:0035723 9.67 JAK3 IL2RG
21 negative regulation of immune response GO:0050777 9.67 IL2RA FOXP3 CTLA4
22 interleukin-7-mediated signaling pathway GO:0038111 9.67 JAK3 IL7R IL7 IL2RG
23 positive regulation of regulatory T cell differentiation GO:0045591 9.66 IL2 FOXP3
24 negative regulation of interleukin-12 production GO:0032695 9.66 JAK3 IL10
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL10 IFNG
26 negative regulation of T cell apoptotic process GO:0070233 9.64 RAG1 IL7R
27 interleukin-9-mediated signaling pathway GO:0038113 9.64 JAK3 IL2RG
28 negative regulation of T-helper 17 cell differentiation GO:2000320 9.63 IL2 FOXP3
29 interleukin-21-mediated signaling pathway GO:0038114 9.62 JAK3 IL2RG
30 positive regulation of T cell differentiation GO:0045582 9.62 RAG1 IL7 IL2RA IL2
31 regulation of complement-dependent cytotoxicity GO:1903659 9.61 IL10 CD55
32 negative regulation of thymocyte apoptotic process GO:0070244 9.61 RAG1 JAK3
33 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2RA IL2 FOXP3
34 necroptotic signaling pathway GO:0097527 9.59 FASLG FAS
35 interleukin-2-mediated signaling pathway GO:0038110 9.56 JAK3 IL2RG IL2RA IL2
36 interleukin-4-mediated signaling pathway GO:0035771 9.55 JAK3 IL2RG
37 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2RA IL2
38 immune response GO:0006955 9.36 RAG1 IL7R IL7 IL2RG IL2RA IL2
39 regulation of regulatory T cell differentiation GO:0045589 9.35 IL2RA IL2 IFNG FOXP3 CTLA4

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 SELL RAG1 RAC2 PTPN22 MYH7 LCK
2 glycosphingolipid binding GO:0043208 9.37 SELL IL2
3 interleukin-2 binding GO:0019976 9.32 IL2RG IL2RA
4 interleukin-2 receptor activity GO:0004911 9.26 IL2RG IL2RA
5 interleukin-7 receptor activity GO:0004917 9.16 IL7R IL2RG
6 cytokine activity GO:0005125 9.02 IL7 IL2 IL10 IFNG FASLG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....